Kymera Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the Annual Meeting of Shareholders held by Kymera Therapeutics, Inc. on June 15, 2023. The filing details the voting results for three proposals submitted to shareholders.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
Shareholders voted on the following three proposals:
- Proposal 1: Election of Class III Directors
- Bruce Booth, D.Phil.: 39,703,629 votes For; 4,484,150 votes Withheld.
- Nello Mainolfi, Ph.D.: 41,999,966 votes For; 2,187,813 votes Withheld.
- John Maraganore, Ph.D.: 34,523,331 votes For; 9,664,448 votes Withheld.
- Elena Ridloff, CFA: 41,783,567 votes For; 2,404,212 votes Withheld.
- All nominees were elected for a three-year term ending in 2026.
- Proposal 2: Advisory Vote on Executive Compensation
- Approved by shareholders on a non-binding basis.
- Results: 42,663,379 votes For; 1,519,388 votes Against; 5,012 Abstain.
- Proposal 3: Ratification of Independent Auditor
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Results: 46,643,302 votes For; 3,214 votes Against; 1,791 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, or specific risk factors beyond the standard disclosure of voting results.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to calculate the percentage of votes cast for each director nominee.
- Review the full Proxy Statement filed on April 27, 2023, for detailed biographies of the elected directors and executive compensation specifics.
- Confirm the term expiration dates for the newly elected Class III directors (2026).